• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[多西环素胸腔内给药后的药代动力学及胸膜反应]

[Pharmacokinetics and pleural reaction of doxycycline after intrapleural administration].

作者信息

Homma T, Yoneda S, Komuro Y, Yoshida S, Min K Y, Takayama S

出版信息

Gan To Kagaku Ryoho. 1983 Apr;10(4 Pt 2):1129-34.

PMID:6870294
Abstract

Tetracycline has been used for the local treatment of malignant pleurisy ever since of Robinson (1972) reported its effectiveness. In this report, we try to elucidate possible mechanisms of action of this drug from the viewpoints of (1) pharmacokinetic analysis following intrapleural administration, and (2) pleural reaction. The results were as follows: (1) In 5 patients with malignant pleural effusion, 500 mg of doxycycline was injected into the pleural cavity and pharmacokinetic analysis was performed. The clearance curve of doxycycline in pleural fluid was described by either a one-compartment model or a two-compartment model. The mean half life of slow space was 33.3 hr, which suggested delayed excretion of this drug from pleural space. (2) The direct effect of doxycycline on pleura was studied in rabbits. At a dose of 10 mg per kg of body weight, the mesothelial cells became cuboid and contained vacuoles in their cytoplasma. With increasing dose up to 40 mg per kg, the changes in mesothelial cells were enhanced. In submesothelial tissue, edema and cellular infiltration were noticed. Three weeks later, normalization of mesothelium was observed, being followed by connective tissue proliferation. These findings may support the efficacy of tetracycline for local treatment of malignant pleurisy.

摘要

自罗宾逊(1972年)报道四环素对恶性胸膜炎的局部治疗有效以来,四环素一直被用于该疾病的治疗。在本报告中,我们试图从以下两个角度阐明该药物可能的作用机制:(1)胸腔内给药后的药代动力学分析;(2)胸膜反应。结果如下:(1)对5例恶性胸腔积液患者胸腔内注射500mg强力霉素,并进行药代动力学分析。胸腔积液中强力霉素的清除曲线可用一室模型或二室模型描述。慢室的平均半衰期为33.3小时,这表明该药物从胸腔内排泄延迟。(2)在兔子身上研究了强力霉素对胸膜的直接作用。当剂量为每公斤体重10mg时,间皮细胞变为立方形,细胞质中出现空泡。随着剂量增加至每公斤体重40mg,间皮细胞的变化加剧。在间皮下组织中,可见水肿和细胞浸润。三周后,观察到间皮恢复正常,随后出现结缔组织增生。这些发现可能支持四环素对恶性胸膜炎局部治疗的疗效。

相似文献

1
[Pharmacokinetics and pleural reaction of doxycycline after intrapleural administration].[多西环素胸腔内给药后的药代动力学及胸膜反应]
Gan To Kagaku Ryoho. 1983 Apr;10(4 Pt 2):1129-34.
2
[Evaluation of local administration of ACNU in the treatment of malignant pleural effusion].[阿糖胞苷局部给药治疗恶性胸腔积液的疗效评估]
Gan To Kagaku Ryoho. 1982 Feb;9(2):316-22.
3
[Aclacinomycin; benefits for the treatment of malignant pleural effusion].[阿克拉霉素;对恶性胸腔积液治疗的益处]
Gan To Kagaku Ryoho. 1983 Aug;10(8):1810-6.
4
[Pharmacokinetics of a new antitumor antibiotic, neothramycin, after intrapleural administration].[新型抗肿瘤抗生素新制癌菌素胸腔内给药后的药代动力学]
Gan To Kagaku Ryoho. 1983 Jun;10(6):1504-10.
5
Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.脂质体包裹的顺铂经胸膜内给药治疗恶性胸腔积液患者的I期临床与药理学研究
Clin Cancer Res. 1997 Mar;3(3):373-9.
6
[The kinetics of IL-2 after pleural administration in the treatment of neoplastic pleurisy].
Rev Mal Respir. 1994;11(1):29-35.
7
Treatment of malignant pleural effusion with doxycycline.
Scand J Infect Dis Suppl. 1988;53:29-34.
8
Single-chain urokinase alone or complexed to its receptor in tetracycline-induced pleuritis in rabbits.单链尿激酶单独或与受体复合后在四环素诱导的兔胸膜炎中的作用
Am J Respir Crit Care Med. 2002 Oct 1;166(7):920-6. doi: 10.1164/rccm.200204-313OC.
9
Comparison of pleurodesis by erythromycin, talc, doxycycline, and diazepam in a rabbit model.红霉素、滑石粉、强力霉素和地西泮在兔模型中胸膜固定术的比较。
J Surg Educ. 2007 Jan-Feb;64(1):41-5. doi: 10.1016/j.cursur.2006.07.006.
10
[Cellular changes in malignant pleural effusion induced by intrapleural injection of BCG-CWS].[卡介苗细胞壁骨架胸膜腔内注射诱导恶性胸腔积液的细胞变化]
Gan No Rinsho. 1983 Aug;29(9):955-61.